ArticleFrontiers in immunology2026
Dynamic immune landscape of NAFLD highlights pDCs as predictive biomarkers for disease progression.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Splenic Steatopathy: A Clinical and Experimental Framework for Lipid-Associated Splenic Pathology.Clinical and experimental gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with profound alterations in the hepatic immune microenvironment; however, a comprehensive understanding of immune cell dynamics across disease stages remains limited. Methods: We performed an integrative reanalysis of publicly available single-cell transcriptomic datasets from the GEO database, encompassing human liver samples spanning the NAFLD continuum. Candidate immune signatures were validated in independent human cohorts and experimentally induced murine NASH models. A diagnostic classifier leveraging pDC associated gene profiles was developed and rigorously evaluated across multiple validation cohorts. Results: Analysis revealed extensive stage-dependent remodeling of hepatic immune composition, with pDCs exhibiting the most pronounced transcriptional and numerical shifts. Specifically, a unique pDC subset coexpressing GZMB and TPM2 was significantly enriched in human NASH samples. This signature was consistently recapitulated in independent human datasets and murine NASH models. The pDC-derived diagnostic model demonstrated robust performance for NASH identification across all validation cohorts. Conclusion: GZMB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.